Search Results

Featured Stories

Toggle

Showing 10 of 86 results

Teva to Present New Data from Growing Mental Health Portfolio at Psych Congress 2021

New Phase 3 RISE study data, post hoc analyses and open-label extension studies to be presented underscore company’s heritage in and commitment to mental health and neuroscience TEL AVIV, Israel &...

Teva to Present 8 Abstracts on AJOVY® (fremanezumab-vfrm) Injection and Hold Symposium on Healthcare Disp

Extension analyses observed patients taking AJOVY experienced a reduction in migraine and headache days and evaluated disability and health-related quality of life Online symposium to highlight...

Late-Breaking Data at the International Headache Society & European Headache Federation Joint Congress 20

Study examined efficacy of AJOVY, atogepant and rimegepant in the prevention of episodic migraine TEL AVIV, Israel & PARSIPPANY, N.J.--(BUSINESS WIRE)-- Teva Pharmaceuticals USA, Inc., a U.S....

Showcasing Teva’s Commitment to Helping Patients Have More Migraine-Free Days, 18 Abstracts will be prese

Late-breaking abstract highlights a network meta-analysis on monthly migraine day reductions with AJOVY, Nurtec ® ODT (Rimegepant) and Atogepant in the preventive treatment of episodic migraine TEL...

New Clinical and Real-World Data Evaluating Efficacy of AJOVY® (fremanezumab-vfrm) Injection Presented at

Findings describe long-term and real-world data across post-hoc and retrospective analyses TEL AVIV, Israel & PARSIPPANY, N.J--(BUSINESS WIRE)-- Teva Pharmaceuticals USA, Inc., a U.S. affiliate of...

Teva to Present Latest Data on AJOVY® (fremanezumab-vfrm) Injection at the 2021 American Headache Society

11 presentations examine clinical and real-world AJOVY data in the reduction of migraine days TEL AVIV, Israel & PARSIPPANY, N.J.--(BUSINESS WIRE)-- Teva Pharmaceuticals USA, Inc., a U.S. affiliate...

Teva to Highlight Research in Respiratory Care at Upcoming 2021 American Thoracic Society International C

Two e-posters include new data across asthma and chronic obstructive pulmonary disease (COPD), emphasizing Teva’s commitment to patients with respiratory diseases TEL AVIV, Israel & PARSIPPANY,...

Teva to Present New Long-Term AUSTEDO® (deutetrabenazine) Tablets Data at American Psychiatric Associatio

Findings evaluate safety, quality of life and patient-centered outcome measures up to 145 weeks TEL AVIV, Israel & PARSIPPANY, N.J.--(BUSINESS WIRE)-- Teva Pharmaceuticals, a U.S. affiliate of Teva...

Teva to Present New Analyses of AUSTEDO® (deutetrabenazine) Tablets and Assessment of Schizophrenia Clini

Four posters examine the long-term efficacy, safety, and tolerability of AUSTEDO in patients with tardive dyskinesia and a review of clinical outcome measures in schizophrenia TEL AVIV, Israel &...

New Clinical and Real-World Data Evaluating Efficacy of AJOVY® (fremanezumab-vfrm) Injection and Reductio

Findings describe long-term and real-world data across post-hoc and retrospective analyses TEL AVIV, Israel & PARSIPPANY, N.J.--(BUSINESS WIRE)-- Teva Pharmaceuticals USA, Inc., a U.S. affiliate of...